Cargando…

Factors Associated With Weight Gain in People Treated With Dolutegravir

BACKGROUND: An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens. METHODS: Adult naïve and experienced people with HIV (PWH) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taramasso, Lucia, Bonfanti, Paolo, Ricci, Elena, Orofino, Giancarlo, Squillace, Nicola, Menzaghi, Barbara, De Socio, Giuseppe Vittorio, Madeddu, Giordano, Pellicanò, Giovanni Francesco, Pagnucco, Layla, Celesia, Benedetto Maurizio, Calza, Leonardo, Conti, Federico, Martinelli, Canio Vito, Valsecchi, Laura, Cascio, Antonio, Bolla, Cesare, Maggi, Paolo, Vichi, Francesca, Dentone, Chiara, Angioni, Goffredo, Mastroianni, Antonio, Falasca, Katia, Cenderello, Giovanni, Di Biagio, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295329/ https://www.ncbi.nlm.nih.gov/pubmed/32577427 http://dx.doi.org/10.1093/ofid/ofaa195

Ejemplares similares

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2019)

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
por: Maggi, Paolo, et al.
Publicado: (2022)

Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
por: Taramasso, Lucia, et al.
Publicado: (2022)

Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
por: De Vito, Andrea, et al.
Publicado: (2023)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project
por: Bagella, Paola, et al.
Publicado: (2018)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
por: Maggi, Paolo, et al.
Publicado: (2023)

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
por: Bonfanti, Paolo, et al.
Publicado: (2020)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Reversibility of Central Nervous System Adverse Events in Course of Art
por: Taramasso, Lucia, et al.
Publicado: (2022)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2018)

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project
por: Squillace, Nicola, et al.
Publicado: (2017)

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort
por: Nicolini, Laura Ambra, et al.
Publicado: (2023)

Weight Gain: A Possible Side Effect of All Antiretrovirals
por: Taramasso, Lucia, et al.
Publicado: (2017)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study
por: De Socio, Giuseppe Vittorio, et al.
Publicado: (2020)

Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study
por: Maggi, Paolo, et al.
Publicado: (2019)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
por: Madeddu, G, et al.
Publicado: (2010)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Ten Years of Medical Informatics and Standards Support for Clinical Research in an Infectious Diseases Network
por: Mora, Sara, et al.
Publicado: (2023)

Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda
por: Guaraldi, Giovanni, et al.
Publicado: (2023)

Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort
por: Focà, Emanuele, et al.
Publicado: (2021)

A comparison of inpatient admissions in 2012 from two European countries
por: Tittle, Victoria, et al.
Publicado: (2014)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting
por: Garagiola, Elisabetta, et al.
Publicado: (2020)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
por: Riccardi, Niccolò, et al.
Publicado: (2019)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation
por: Cenderello, Giovanni, et al.
Publicado: (2015)

The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials
por: Fraccaro, Paolo, et al.
Publicado: (2013)

96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
por: Capetti, Amedeo, et al.
Publicado: (2012)

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis
por: Cenderello, Giovanni, et al.
Publicado: (2017)

Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL
por: Dentone, Chiara, et al.
Publicado: (2014)

Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region
por: Vena, Antonio, et al.
Publicado: (2021)

Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?
por: Di Biagio, Antonio, et al.
Publicado: (2017)

HIV and SARS-CoV-2 Co-Infection: What are the Risks?
por: Squillace, Nicola, et al.
Publicado: (2021)

The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data
por: Capici, Serena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_loeqeen1inlvc51i1b3uc6ug8b